CoChat

Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint

Open access
Kleiblova, Petra, Shaltiel, Indra A., Benada, Jan, Ševčík, Jan, Pecháčková, Soňa, Pohlreich, Petr, Voest, Emile E., Dundr, Pavel, Bartek, Jiri, Kleibl, Zdenek, Medema, René H., Macurek, Libor · 2013 · Journal of Cell Biology

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

The DNA damage response (DDR) pathway and its core component tumor suppressor p53 block cell cycle progression after genotoxic stress and represent an intrinsic barrier preventing cancer development. The serine/threonine phosphatase PPM1D/Wip1 inactivates p53 and promotes termination of the DDR pathway. Wip1 has been suggested to act as an oncogene in a subset of tumors that retain wild-type p53. In this paper, we have identified novel gain-of-function mutations in exon 6 of PPM1D that result in expression of C-terminally truncated Wip1. Remarkably, mutations in PPM1D are present not only in the tumors but also in other tissues of breast and colorectal cancer patients, indicating that they arise early in development or affect the germline. We show that mutations in PPM1D affect the DDR pathway and propose that they could predispose to cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1083/jcb.201210031

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The PPM1D gene is mutated in selected cancer cell lines. (A) Whole-cell lysates from indicated cell lines were probed with anti-Wip1 (Bethyl Laboratories, Inc.), anti-Wip1 (Santa Cruz Biotechnology, Inc. [SC]), and anti–14-3-3 (loading control) antibodies. Note the additional Wip1-reactive band around 60 kD in U2OS and HCT116 cells. PC3 cells are p53 negative and served as a control. (B) Wip1 was depleted in U2OS and HCT116 cells by siRNA, and lysates were probed with the indicated antibodies. (C) Sequencing chromatograms of PPM1D from genomic DNA isolated from U2OS and HCT116 cells. Numbering is based on NCBI GenBank reference sequence NT_010783.15. Mutations are indicated by arrowheads and underlined. WT, wild-type PPM1D; Mut, mutated PPM1D; c., nucleotide sequence; p., Wip1 peptide sequence.
Figure 1. The PPM1D gene is mutated in selected cancer cell lines. (A) Whole-cell lysates from indicated cell lines were probed with anti-Wip1 (Bethyl Laboratories, Inc.), anti-Wip1 (Santa Cruz Biotechnology, Inc. [SC]), and anti–14-3-3 (loading control) antibodies. Note the additional Wip1-reactive band around 60 kD in U2OS and HCT116 cells. PC3 cells are p53 negative and served as a control. (B) Wip1 was depleted in U2OS and HCT116 cells by siRNA, and lysates were probed with the indicated antibodies. (C) Sequencing chromatograms of PPM1D from genomic DNA isolated from U2OS and HCT116 cells. Numbering is based on NCBI GenBank reference sequence NT_010783.15. Mutations are indicated by arrowheads and underlined. WT, wild-type PPM1D; Mut, mutated PPM1D; c., nucleotide sequence; p., Wip1 peptide sequence.CC BY-NC-SA · PubMed Central
Figure 2. Truncated Wip1 mutants are enzymatically active. (A) Soluble and chromatin fractions from cells expressing FL or truncated FLAG-Wip1 were probed with the indicated antibodies. (B) Cells expressing EGFP-Wip1-FL (FL), EGFP-Wip1-D314A (phosphatase dead), or truncated EGFP-Wip1 were fixed 3 h after irradiation (3 Gy). 53BP1 nuclear foci were counted by automated image analysis (1,000 cells per condition). Average number of 53BP1 foci per nucleus in transfected (GFP+) and neighboring control cells (GFP−) is shown. (C) Expression of Wip1-FL, Wip1-D314A, or truncated FLAG-Wip1 was induced by tetracycline 12 h before irradiation (3 Gy). Whole-cell lysates were probed with the indicated antibodies. (D) Phosphatase activity of immunopurified FLAG-Wip1-FL, -L450X, -R458X, or -D314A (phosphatase dead) was measured in vitro using a synthetic phosphopeptide corresponding to pSer15-p53 (bottom), and the precipitated material was probed with anti-Wip1 antibody as a control of equal loading (top). n = 4. (E) Quantification of the signal intensity corresponding to the endogenous levels of FL and truncated Wip1 in HCT116 and U2OS cells. siRNA of Wip1 was used as a control of the signal specificity. Error bars indicate standard deviations. mut, mutated; WT, wild type.
Figure 2. Truncated Wip1 mutants are enzymatically active. (A) Soluble and chromatin fractions from cells expressing FL or truncated FLAG-Wip1 were probed with the indicated antibodies. (B) Cells expressing EGFP-Wip1-FL (FL), EGFP-Wip1-D314A (phosphatase dead), or truncated EGFP-Wip1 were fixed 3 h after irradiation (3 Gy). 53BP1 nuclear foci were counted by automated image analysis (1,000 cells per condition). Average number of 53BP1 foci per nucleus in transfected (GFP+) and neighboring control cells (GFP−) is shown. (C) Expression of Wip1-FL, Wip1-D314A, or truncated FLAG-Wip1 was induced by tetracycline 12 h before irradiation (3 Gy). Whole-cell lysates were probed with the indicated antibodies. (D) Phosphatase activity of immunopurified FLAG-Wip1-FL, -L450X, -R458X, or -D314A (phosphatase dead) was measured in vitro using a synthetic phosphopeptide corresponding to pSer15-p53 (bottom), and the precipitated material was probed with anti-Wip1 antibody as a control of equal loading (top). n = 4. (E) Quantification of the signal intensity corresponding to the endogenous levels of FL and truncated Wip1 in HCT116 and U2OS cells. siRNA of Wip1 was used as a control of the signal specificity. Error bars indicate standard deviations. mut, mutated; WT, wild type.CC BY-NC-SA · PubMed Central
Figure 3. Truncated Wip1 mutants show increased protein stability. (A) HCT116 and U2OS cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed using the monoclonal anti-Wip1 antibody (Santa Cruz Biotechnology, Inc. [SC]). (B) Signal intensity corresponding to the FL-Wip1 and truncated Wip1 from A was quantified using ImageJ software. The relative change in signal intensity is shown. Statistical significance was determined by unpaired two-tailed t test (n = 3; *, P < 0.05). (C) U2OS cells were treated with cycloheximide, proteasomal inhibitor MG132 or a combination of both for the indicated times and analyzed as in A. (D) U2OS cells were transfected with plasmid DNA coding for EGFP or EGFP fused to the C-terminal region of Wip1 (aa 380–605). Cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed with an anti-GFP antibody, and the signal intensity was quantified using ImageJ software. n = 3. Error bars indicate standard deviations. exp., exposure.
Figure 3. Truncated Wip1 mutants show increased protein stability. (A) HCT116 and U2OS cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed using the monoclonal anti-Wip1 antibody (Santa Cruz Biotechnology, Inc. [SC]). (B) Signal intensity corresponding to the FL-Wip1 and truncated Wip1 from A was quantified using ImageJ software. The relative change in signal intensity is shown. Statistical significance was determined by unpaired two-tailed t test (n = 3; *, P < 0.05). (C) U2OS cells were treated with cycloheximide, proteasomal inhibitor MG132 or a combination of both for the indicated times and analyzed as in A. (D) U2OS cells were transfected with plasmid DNA coding for EGFP or EGFP fused to the C-terminal region of Wip1 (aa 380–605). Cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed with an anti-GFP antibody, and the signal intensity was quantified using ImageJ software. n = 3. Error bars indicate standard deviations. exp., exposure.CC BY-NC-SA · PubMed Central
Figure 4. Mutated Wip1 impairs the p53-dependent G1 checkpoint. (A) U2OS cells were transfected by siRNA targeting luciferase, Wip1 and/or p53 and grown for 48 h. Cells were treated with BrdU and STLC, irradiated or not irradiated with 4 Gy, and grown for a further 16 h. Cells were analyzed by immunoblotting (top) or by flow cytometry (bottom) to determine the fraction of G1 cells (2n; BrdU negative). (B) U2OS cells were transfected by siRNA targeting various isoforms of Wip1, irradiated, and probed with the indicated antibodies (left) or analyzed by cytometry (right). The fraction of BrdU-negative 2n cells corresponds to cells arrested in G1. (C, left) FUCCI-expressing HCT116 cells were transfected with Wip1 or luciferase siRNA (siLuc), irradiated (4 Gy), and followed by live-cell imaging. Cumulative progression into S phase was determined based on the loss of FUCCI-G1 marker (red) and appearance of the FUCCI-S/G2 marker (green) Numbers of analyzed cells are indicated in parentheses. (right) Representative images of four individual cells transfected with Wip1 or Luciferase siRNA are shown. Bars, 10 µm. (D) Retinal pigment epithelium (RPE1), U2OS, and HCT116 cells were transfected with Wip1 or luciferase siRNA and grown for 48 h before irradiation (5 Gy). Cells were fixed 4 h after IR and probed for total p53 and p21. Bars, 50 µm. (E) U2OS cells were treated as in D, collected 6 h after IR, and probed with the indicated antibodies. SC, Santa Cruz Biotechnology, Inc.
Figure 4. Mutated Wip1 impairs the p53-dependent G1 checkpoint. (A) U2OS cells were transfected by siRNA targeting luciferase, Wip1 and/or p53 and grown for 48 h. Cells were treated with BrdU and STLC, irradiated or not irradiated with 4 Gy, and grown for a further 16 h. Cells were analyzed by immunoblotting (top) or by flow cytometry (bottom) to determine the fraction of G1 cells (2n; BrdU negative). (B) U2OS cells were transfected by siRNA targeting various isoforms of Wip1, irradiated, and probed with the indicated antibodies (left) or analyzed by cytometry (right). The fraction of BrdU-negative 2n cells corresponds to cells arrested in G1. (C, left) FUCCI-expressing HCT116 cells were transfected with Wip1 or luciferase siRNA (siLuc), irradiated (4 Gy), and followed by live-cell imaging. Cumulative progression into S phase was determined based on the loss of FUCCI-G1 marker (red) and appearance of the FUCCI-S/G2 marker (green) Numbers of analyzed cells are indicated in parentheses. (right) Representative images of four individual cells transfected with Wip1 or Luciferase siRNA are shown. Bars, 10 µm. (D) Retinal pigment epithelium (RPE1), U2OS, and HCT116 cells were transfected with Wip1 or luciferase siRNA and grown for 48 h before irradiation (5 Gy). Cells were fixed 4 h after IR and probed for total p53 and p21. Bars, 50 µm. (E) U2OS cells were treated as in D, collected 6 h after IR, and probed with the indicated antibodies. SC, Santa Cruz Biotechnology, Inc.CC BY-NC-SA · PubMed Central
Figure 5. Truncation mutations of Wip1 are present in cancer patients. (A) Chromatograms of four truncating mutations identified by screening of the PPM1D gene in cancer patients. Mutations are indicated by arrowheads and underlined. WT, wild-type PPM1D; Mut, mutated PPM1D; c., nucleotide sequence; p., Wip1 peptide sequence. (B) Cells expressing EGFP–Wip1-FL, -R458X, -L484X, -F534X, or -K535X mutants were irradiated, and the number of 53BP1 foci was analyzed as in Fig. 2 B. (C) FLAG–Wip1-FL, -R458X, -L484X, -F534X, or -K535X mutants were immunoprecipitated, and phosphatase activity was determined as in Fig. 2 D. (D) Wip1 expression in leukocytes from a healthy control or the #BRCA1855 patient was analyzed by immunoblotting. The asterisk indicates a cross-reacting band in the blood sample. Note the increased expression level of the truncated Wip1 in leukocytes from cancer patient. (E) Mutation of PPM1D was analyzed in microdissected mammary noncancer tissue and in cancer tissue from the #BRCA1855 patient. Error bars indicate standard deviations.
Figure 5. Truncation mutations of Wip1 are present in cancer patients. (A) Chromatograms of four truncating mutations identified by screening of the PPM1D gene in cancer patients. Mutations are indicated by arrowheads and underlined. WT, wild-type PPM1D; Mut, mutated PPM1D; c., nucleotide sequence; p., Wip1 peptide sequence. (B) Cells expressing EGFP–Wip1-FL, -R458X, -L484X, -F534X, or -K535X mutants were irradiated, and the number of 53BP1 foci was analyzed as in Fig. 2 B. (C) FLAG–Wip1-FL, -R458X, -L484X, -F534X, or -K535X mutants were immunoprecipitated, and phosphatase activity was determined as in Fig. 2 D. (D) Wip1 expression in leukocytes from a healthy control or the #BRCA1855 patient was analyzed by immunoblotting. The asterisk indicates a cross-reacting band in the blood sample. Note the increased expression level of the truncated Wip1 in leukocytes from cancer patient. (E) Mutation of PPM1D was analyzed in microdissected mammary noncancer tissue and in cancer tissue from the #BRCA1855 patient. Error bars indicate standard deviations.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • WAF1, a potential mediator of p53 tumor suppression

    El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · cited 2×

    “Although high doses of DNA damage (such as therapeutic irradiation or radiomimetic drugs) lead to p53-induced programmed cell death or permanent withdrawal from the cell cycle (senescence), more moderate DNA damage (originating from erroneous DNA metabolism or from environmental factors) triggers expression of DNA rep…”
  • p53 Mutations in Human Cancers

    Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×

    “The most common example of such DDR defect is an inactivating somatic mutation in the TP53 gene that disables proper response to genotoxic stress, leads to genomic instability, and is found in about half of human tumors (Hollstein et al., 1991).”
  • Surfing the p53 network

    Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×

    “In general, genotoxic stress induces stabilization, oligomerization, and binding of p53 to promoters, causing a widespread modulation of gene expression (Vogelstein et al., 2000).”
  • The DNA-damage response in human biology and disease

    Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 2×

    “…ATM (ataxia telangiectasia mutated)/Chk2, ATR (ataxia telangiectasia and Rad3 related)/Chk1, and p38/ MK2 kinases converges on the tumor suppressor p53, which plays a central role in regulating cell fate decisions in response to genotoxic stress (Jackson and Bartek, 2009; Medema and Macůrek, 2012).”
  • Cancer genes and the pathways they control

    Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×

    “Whereas tumor development is substantially boosted by inactivation of the second allele of the tumor suppressor genes, monoallelic gain-offunction mutations are usually sufficient to activate oncogenes (Vogelstein and Kinzler, 2004).”
  • DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

    Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 2×

    “…identified oncogene-induced replication stress and DNA breakage that trigger the DDR as an intrinsic barrier against progression of early preinvasive stages of solid tumors to malignant lesions (Bartkova et al., 2005, 2006; Gorgoulis et al., 2005; Di Micco et al., 2006; Halazonetis et al., 2008).”
  • Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression

    Sakaue-Sawano, A., Kurokawa, H., Morimura, T., Hanyu, A., Hama, H., Osawa, H., Kashiwagi, S., Fukami, K., Miyata, T., Miyoshi, H., et al. (2008) · Cell · doi:10.1016/j.cell.2007.12.033 · Cited by 2,173 · cited 2×

    “A stable cell line expressing the fluorescent, ubiquitination-based cell cycle indicator (FUCCI) was generated by transduction of HCT116 cells with pCSII-EF-MCS-mKO2hCdt1(30–120) and pCSII-EF-MCS-mAG-hGeminin(1–110) plasmids (Sakaue-Sawano et al., 2008) followed by FACS sorting of double-positive cells from which a si…”
  • Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

    Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009

  • Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

    Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 1×

    “…identified oncogene-induced replication stress and DNA breakage that trigger the DDR as an intrinsic barrier against progression of early preinvasive stages of solid tumors to malignant lesions (Bartkova et al., 2005, 2006; Gorgoulis et al., 2005; Di Micco et al., 2006; Halazonetis et al., 2008).”
  • Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A

    Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966 · cited 1×

    “For example, germline mutations of oncogenic tyrosine kinases RET, MET, and KIT are linked with medullary thyroid carcinoma, hereditary papillary renal carcinoma, and hereditary gastrointestinal stromal tumor syndrome, respectively (Mulligan et al., 1993; Schmidt et al., 1997; Nishida et al., 1998).”

Show all 38 references

Cited by

Metadata

Authors
Kleiblova, P., Shaltiel, I. A., Benada, J., &#x8a;evčík, J., Pecháčková, S., Pohlreich, P., Voest, E. E., Dundr, P., Bartek, J., Kleibl, Z., Medema, R. H., & Macurek, L.
Affiliations
  • Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, CZ-12853 Prague, Czech Republic 1
  • Division of Cell Biology, The Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands 2
  • Czech Academy of Sciences (CZ)
  • Charles University (CZ)
  • University Medical Center Utrecht (NL)
  • Department of Cancer Cell Biology 4 and 5
  • The Netherlands Cancer Institute (NL)
Corresponding author
Medema, René H.
Venue
Journal of Cell Biology
Published
2013-05-06
Volume
201
Issue
4
Pages
511-521
ISSN
  • 0021-9525 (ISSN-L)
  • 1540-8140
OpenAlex
W2096812573
Cited by
170
References
39
Citations by year
2026: 8 · 2025: 11 · 2024: 25 · 2023: 12 · 2022: 10 · 2021: 11 · 2020: 12 · 2019: 12 · 2018: 11 · 2017: 13 · 2016: 12 · 2015: 11 · 2014: 17 · 2013: 5
FWCI
8.04
Type
journal article
Language
en
Open access
Locations
  • The Journal of Cell Biology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • ASEP (submittedVersion, public-domain)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
PPM1D, Wip1, gain-of-function mutations, p53, G1/S checkpoint, DNA damage response, tumor suppressor inactivation, breast cancer, colorectal cancer, germline mutations, cancer susceptibility, cell cycle arrest
MeSH terms
Protein Phosphatase 2C, Cell Cycle, DNA Damage, HeLa Cells, Humans, Mutation, Neoplasms, Phosphoprotein Phosphatases, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, G1 Phase, Genetic Predisposition to Disease, Cell Line, Tumor, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.